About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT00984867

Dapagliflozin DPPIV Inhibitor add-on Study

This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The ef...

Lead sponsor: AstraZeneca•45 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

AstraZeneca

Collaborators

Bristol-Myers Squibb

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with type 2 diabetes
•Patients who are not receiving treatment , or those who currently receive metformin, sitagliptin or vildagliptin or the combination of these
•Patients will be screened by a blood test and only those who need additional therapy can be enrolled

Exclusion Criteria

•Patients with type 1 diabetes
•Patients with very poorly controlled diabetes
•Any clinically significant illness, which in the judgement of the investigator would compromise the patient's safety or successful participation in the clinical study

Related studies

Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD

NCT07187830 · Chronic Kidney Disease in Type 2 Diabetes, Obesity & Overweight

RECRUITINGPhase 4

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

NCT06613854 · Type 2 Diabetes Mellitus (T2DM)

Using Virtual Reality to Improve Medical Training

NCT07542834 · Type 2 Diabetes (T2DM), Geriatric Syndromes, and more

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

NCT07272837 · Type 2 Diabetes, Obesity, and more

An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea

NCT07232537 · Chronic Kidney Disease, Type 2 Diabetes Mellitus

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 13, 2014Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment833

Start dateOct 2009

Last updatedJun 13, 2014

Condition

Type 2 Diabetes

Locations shown

Research Site

Huntsville, Alabama

Research Site

Ozark, Alabama

Research Site

Anaheim, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 13, 2014Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions